FTFinancial Times·1hBusiness
score-0.30
Novo’s Guidance Remains Unambitious as Company Broadens Focus Beyond Weight-Loss Drugs
Original
Novo’s prospects beyond weight-loss drugs look surprisingly lean
“Uses terms like 'lean' and 'unambitious' to frame corporate expansion efforts as insufficient and stagnant.”